Publications 2023

Trewin-Nybråten CB, Larsen IK, Møller B, Heikkilä R (2023)
Hospital surgical volume and colorectal cancer survival in Norway: A nationwide cohort study
Cancer Epidemiol, 85, 102404
DOI 10.1016/j.canep.2023.102404, PubMed 37343490

Publications 2022

Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L et al. (2022)
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial
Radiother Oncol, 172, 1-9
DOI 10.1016/j.radonc.2022.04.020, PubMed 35476942

Publications 2021

Gjersvik P, Heikkila R, Johansen TEB (2021)
Rescue treatment for cancer
Tidsskr. Nor. Laegeforen., 141 (5), 487

Heikkilä R, Myklebust TÅ, Møller B (2021)
Regional variation in cancer survival in Norway
Cancer Epidemiol, 75, 102038
DOI 10.1016/j.canep.2021.102038, PubMed 34571393

Publications 2020

De Bruycker A, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, Gomez-Iturriaga A, Everaerts W, Otte F, Papachristofilou A, Scorsetti M, Shelan M, Siva S, Ameye F, Guckenberger M, Heikkilä R, Putora PM, Zapatero A, Conde-Moreno A, Couñago F, Vanhoutte F, Goetghebeur E, Reynders D, Zilli T, Ost P (2020)
PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
BMC Cancer, 20 (1), 406
DOI 10.1186/s12885-020-06911-4, PubMed 32398040

Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A et al. (2020)
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases
Eur Urol Focus, 7 (2), 241-244
DOI 10.1016/j.euf.2020.12.010, PubMed 33386290

Publications 2018

Oltedal S, Kørner H, Aasprong OG, Hussain I, Tjensvoll K, Smaaland R, Søreide JA, Søreide K, Lothe RA, Heikkilä R, Gilje B, Nordgård O (2018)
The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer
Transl Oncol, 11 (2), 436-443
DOI 10.1016/j.tranon.2018.01.015, PubMed 29475140

Oltedal S, Skaland I, Maple-Grødem J, Tjensvoll K, Janssen EAM, Gilje B, Smaaland R, Heikkilä R, Nordgård O (2018)
Expression profiling and intracellular localization studies of the novel Proline-, Histidine-, and Glycine-rich protein 1 suggest an essential role in gastro-intestinal epithelium and a potential clinical application in colorectal cancer diagnostics
BMC Gastroenterol, 18 (1), 26
DOI 10.1186/s12876-018-0752-8, PubMed 29415677

Publications 2017

Heikkilä R, Kaasa S (2017)
Chemotherapy in end-of-life care
Ann Oncol, 28 (4), 684-685
DOI 10.1093/annonc/mdx039, PubMed 28327919

Publications 2012

Nordgård O, Oltedal S, Aasprong OG, Søreide JA, Søreide K, Tjensvoll K, Gilje B, Heikkilä R, Guriby M, Lothe RA, Smaaland R, Kørner H (2012)
Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients
Ann Surg Oncol, 19 (12), 3719-26
DOI 10.1245/s10434-012-2454-8, PubMed 22752373

Publications 2011

Oltedal S, Aasprong OG, Møller JH, Kørner H, Gilje B, Tjensvoll K, Birkemeyer EM, Heikkilä R, Smaaland R, Nordgård O (2011)
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy
Int J Colorectal Dis, 26 (10), 1271-7
DOI 10.1007/s00384-011-1233-5, PubMed 21573767

Publications 2010

Oltedal S, Gilje B, Kørner H, Aasprong OG, Tjensvoll K, Heikkilä R, Smaaland R, Nordgård O (2010)
Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR
Ann Surg, 251 (6), 1087-91
DOI 10.1097/SLA.0b013e3181dae1bc, PubMed 20485143

Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkilä R, Kvaløy JT, Gilje B, Smaaland R, Nordgård O (2010)
Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients
Clin Breast Cancer, 10 (5), 378-84
DOI 10.3816/CBC.2010.n.050, PubMed 20920982

Publications 2009

Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R (2009)
The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR
Int J Colorectal Dis, 24 (3), 261-8
DOI 10.1007/s00384-008-0613-y, PubMed 19119477

Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R (2009)
Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach
Ann Surg, 249 (4), 602-7
DOI 10.1097/SLA.0b013e31819ec923, PubMed 19300229

Publications 2008

Gilje B, Heikkilä R, Oltedal S, Tjensvoll K, Nordgård O (2008)
High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations
J Mol Diagn, 10 (4), 325-31
DOI 10.2353/jmoldx.2008.070183, PubMed 18556764

Glimelius B, Sørbye H, Balteskard L, Byström P, Pfeiffer P, Tveit K, Heikkilä R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A (2008)
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Ann Oncol, 19 (5), 909-14
DOI 10.1093/annonc/mdm588, PubMed 18209013

Tjensvoll K, Gilje B, Oltedal S, Shammas VF, Kvaløy JT, Heikkilä R, Nordgård O (2008)
A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow
Breast Cancer Res Treat, 116 (2), 329-38
DOI 10.1007/s10549-008-0204-1, PubMed 18846421

Publications 2007

Farmen RK, Nordgård O, Gilje B, Shammas FV, Kvaløy JT, Oltedal S, Heikkilä R (2007)
Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients
Breast Cancer Res Treat, 108 (2), 251-8
DOI 10.1007/s10549-007-9592-x, PubMed 17492378

Publications 1993

Heikkilä R, Heilo A, Stenwig AE, Fosså SD (1993)
Testicular ultrasonography and 18G biopty biopsy for clinically undetected cancer or carcinoma in situ in patients with germ cell tumours
Br J Urol, 71 (2), 214-6
DOI 10.1111/j.1464-410x.1993.tb15921.x, PubMed 8384915